Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit
Open Access
- 27 August 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (17) , 6803-6818
Abstract
A novel series of potent chiral inhibitors of histone deacetylase (HDAC) is described that contains an oxazoline capping group and a N-(2-aminophenyl)-benzamide unit. Among several new inhibitors of this type exhibiting Class I selectivity and potent inhibition of HDAC3-NCoR2, in vitro assays for the inhibition of HDAC1, HDAC2, and HDAC3-NCoR2 by N-(2-aminophenyl)-benzamide 15k gave respective IC50 values of 80, 110, and 6 nM. Weak inhibition of all other HDAC isoforms (HDAC4, 5, 6, 7, and 9: IC50 > 100 000 nM; HDAC8: IC50 = 25 000 nM; HDAC10: IC50 > 4000 nM; HDAC11: IC50 > 2000 nM) confirmed the Class I selectivity of 15k. 2-Aminoimidazolinyl, 2-thioimidazolinyl, and 2-aminooxazolinyl units were shown to be effective replacements for the pyrimidine ring present in many other 2-(aminophenyl)-benzamides previously reported, but the 2-aminooxazolinyl unit was the most potent in inhibiting HDAC3-NCoR2. Many of the new HDAC inhibitors showed higher solubilities and lower binding to human serum albumin than that of Mocetinostat. Increases in histone H3K9 acetylation in the human cell lines U937 and PC-3 was observed for all three oxazolinyl inhibitors evaluated; those HDAC inhibitors also lowered cyclin E expression in U937 cells but not in PC-3 cells, indicating underlying differences in the mechanisms of action of the inhibitors on those two cell lines.Keywords
Funding Information
- Leukaemia and Lymphoma Research
- Biotechnology and Biological Sciences Research Council
- GlaxoSmithKline
- Engineering and Physical Sciences Research Council
This publication has 55 references indexed in Scilit:
- Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for CancerAnti-Cancer Agents in Medicinal Chemistry, 2009
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen speciesProceedings of the National Academy of Sciences, 2001
- Translating the Histone CodeScience, 2001
- Histone Acetylation Modifiers in the Pathogenesis of Malignant DiseaseMolecular Medicine, 2000
- Mutations truncating the EP300 acetylase in human cancersNature Genetics, 2000
- The language of covalent histone modificationsNature, 2000
- Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACsCurrent Opinion in Chemical Biology, 1997
- A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3pScience, 1996